The nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway is one of the primary pathways responsible for the cellular defense system against oxidative stress. Oxidative stress-induced apoptosis is a causal event in diabetic embryopathy. Thus, the Nrf2 pathway may play an important role in the induction of diabetic embryopathy. In the present study, we investigated the potentially protective effect of the Nrf2 activator, vinylsulfone, on high glucose-induced cellular stress, apoptosis, and neural tube defects (NTDs). Embryonic day 8.5 (E8.5) whole mouse embryos were cultured in normal (5 mmol/L) or high (16.7 mmol/L) glucose conditions, with or without vinylsulfone. At a concentration of 10 μmol/L, vinylsulfone had an inhibitory effect on high glucose-induced NTD formation, but it was not significant. At a concentration of 20 μmol/L, vinylsulfone significantly reduced high glucose-induced NTDs. In addition, 20 μmol/L vinylsulfone abrogated the high glucose-induced oxidative stress markers lipid hydroperoxide (LPO), 4-hydroxynonenal (4-HNE), and nitrotyrosine-modified proteins. The high glucose-induced endoplasmic reticulum (ER) stress biomarkers were also suppressed by 20 μmol/L vinylsulfone through the inhibition of phosphorylated protein kinase RNA-like ER kinase (PERK), inositol requiring protein 1α (IRE1a), eukaryotic initiation factor 2α (eIF2a), upregulated C/EBP-homologous protein (CHOP), binding immunoglobulin protein (BiP), and x-box binding protein 1 (XBP1) messenger RNA splicing. Furthermore, 20 μmol/L vinylsulfone abolished caspase 3 and caspase 8 cleavage, markers of apoptosis, in embryos cultured under high glucose conditions. The Nrf2 activator, vinylsulfone, is protective against high glucose-induced cellular stress, caspase activation, and subsequent NTD formation. Our data suggest that vinylsulfone supplementation is a potential therapy for diabetes-associated neurodevelopmental defects.
YangPReeceEAWangFGabbay-BenzivR. Decoding the oxidative stress hypothesis in diabetic embryopathy through proapoptotic kinase signaling. Am J Obstetr Gynecol. 2015;212(5):569–579.
2.
WangFReeceEAYangP. Advances in revealing the molecular targets downstream of oxidative stress-induced proapoptotic kinase signaling in diabetic embryopathy. Am J Obstet Gynecol. 2015;213(2):125–134.
3.
Gabbay-BenzivRReeceEAWangFYangP. Birth defects in pregestational diabetes: Defect range, glycemic threshold and pathogenesis. World J Diabetes. 2015;6(3):481–488.
4.
DincerYAkcayTAlademirZIlkovaH. Assessment of DNA base oxidation and glutathione level in patients with type 2 diabetes. Mutat Res. 2002;505(1-2):75–81.
5.
SakamakiHAkazawaSIshibashiM. Significance of glutathione-dependent antioxidant system in diabetes-induced embryonic malformations. Diabetes. 1999;48(5):1138–1144.
6.
WolffSP.Diabetes mellitus and free radicals. Free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications. Br Med Bull. 1993;49(3):642–652.
7.
BaynesJW. Role of oxidative stress in development of complications in diabetes. Diabetes. 1991;40(4):405–412.
8.
DrogeW. Free radicals in the physiological control of cell function. Physiol Rev. 2002;82(1):47–95.
9.
EvansJLGoldfineIDMadduxBAGrodskyGM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002;23(5):599–622.
10.
DongJSulikKKChenSY. Nrf2-mediated transcriptional induction of antioxidant response in mouse embryos exposed to ethanol in vivo: implications for the prevention of fetal alcohol spectrum disorders. Antioxid Redox Signal. 2008;10(12):2023–2033.
11.
WangFFisherSAZhongJWuYYangP. Superoxide Dismutase 1 in vivo Ameliorates Maternal Diabetes-Induced Apoptosis and Heart Defects through Restoration of Impaired Wnt Signaling. Circ Cardiovasc Genet. 2015;8(5):665–676.
12.
DongDReeceEALinXWuYAriasVillelaNYangP. New development of the yolk sac theory in diabetic embryopathy: molecular mechanism and link to structural birth defects[published online September 30, 2015]. Am J Obstet Gynecol. 2015.
13.
PinterEReeceEALeranthCZ. Yolk sac failure in embryopathy due to hyperglycemia: ultrastructural analysis of yolk sac differentiation associated with embryopathy in rat conceptuses under hyperglycemic conditions. Teratology. 1986;33(1):73–84.
14.
ReeceEAPinterELeranthCZ. Ultrastructural analysis of malformations of the embryonic neural axis induced by in vitro hyperglycemic conditions. Teratology. 1985;32(3):363–373.
15.
LiJWangJJYuQWangMZhangSX. Endoplasmic reticulum stress is implicated in retinal inflammation and diabetic retinopathy. FEBS Lett. 2009;583(9):1521–1527.
16.
LupachykSWatchoPStavniichukRShevalyeHObrosovaIG. Endoplasmic reticulum stress plays a key role in the pathogenesis of diabetic peripheral neuropathy. Diabetes. 2013;62(3):944–952.
17.
WangFReeceEAYangP. Superoxide dismutase 1 overexpression in mice abolishes maternal diabetes-induced endoplasmic reticulum stress in diabetic embryopathy. Am J Obstet Gynecol. 2013;209(4):345. e1-e7.
18.
LiXXuCYangP. c-Jun NH2-terminal kinase 1/2 and endoplasmic reticulum stress as interdependent and reciprocal causation in diabetic embryopathy. Diabetes. 2013;62(2):599–608.
19.
WangFWuYQuonMJLiXYangP. ASK1 mediates the teratogenicity of diabetes in the developing heart by inducing ER stress and inhibiting critical factors essential for cardiac development. Am J Physiol Endocrinol Metab. 2015;309(5):E487–E499.
20.
WuYWangFFuMWangCQuonMJYangP. Cellular stress, excessive apoptosis, and the effect of metformin in a mouse model of type 2 diabetic embryopathy. Diabetes. 2015;64(7):2526–2536.
21.
WuYWangFReeceEAYangP. Curcumin ameliorates high glucose-induced neural tube defects by suppressing cellular stress and apoptosis. Am J Obstet Gynecol. 2015;212(6):802. e1–e8.
22.
GuHYuJDongDZhouQWangJYYangP. The miR-322-TRAF3 circuit mediates the pro-apoptotic effect of high glucose on neural stem cells. Toxicol Sci. 2015;144(1):186–196.
23.
WangFWuYGuH. Ask1 gene deletion blocks maternal diabetes-induced endoplasmic reticulum stress in the developing embryo by disrupting the unfolded protein response signalosome. Diabetes. 2015;64(3):973–988.
24.
YangPLiXXuCReeceEAZielkeHRWangF. Maternal hyperglycemia activates an ASK1-FoxO3a-caspase 8 pathway that leads to embryonic neural tube defects. Sci Signal. 2013;6(290):ra74.
25.
WangFWengHQuonMJ. Dominant negative FADD dissipates the proapoptotic signalosome of the unfolded protein response in diabetic embryopathy. Am J Physiol Endocrinol Metab. 2015;309(10):E861–E873.
26.
GuHYuJDongD. High glucose-repressed CITED2 expression through miR-200b triggers the unfolded protein response and endoplasmic reticulum stress. Diabetes. 2016;65(1):149–163.
27.
LiXWengHReeceEAYangP. SOD1 overexpression in vivo blocks hyperglycemia-induced specific PKC isoforms: substrate activation and consequent lipid peroxidation in diabetic embryopathy. Am J Obstet Gynecol. 2011;205(1):84. e1–e6.
28.
YangPLiH. Epigallocatechin-3-gallate ameliorates hyperglycemia-induced embryonic vasculopathy and malformation by inhibition of Foxo3a activation. Am J Obstet Gynecol. 2010;203(1):75. e1–e6.
29.
ReeceEAWuYKZhaoZDhanasekaranD. Dietary vitamin and lipid therapy rescues aberrant signaling and apoptosis and prevents hyperglycemia-induced diabetic embryopathy in rats. Am J Obstet Gynecol. 2006;194(2):580–585.
30.
ReeceEAWuYKWiznitzerA. Dietary polyunsaturated fatty acid prevents malformations in offspring of diabetic rats. Am J Obstet Gynecol. 1996;175(4 pt 1):818–823.
31.
XuCLiXWangFWengHYangP. Trehalose prevents neural tube defects by correcting maternal diabetes-suppressed autophagy and neurogenesis. Am J Physiol Endocrinol Metab. 2013;305(5):E667–E678.
32.
CorreaABottoLLiuYMulinareJEricksonJD. Do multivitamin supplements attenuate the risk for diabetes-associated birth defects?Pediatrics. 2003;111(5 pt 2):1146–1151.
33.
ZhongJReeceEAYangP. Punicalagin exerts protective effect against high glucose-induced cellular stress and neural tube defects. Biochem Biophys Res Commun. 2015;467(2):179–184.
34.
GrodsteinFO’BrienJKangJH. Long-term multivitamin supplementation and cognitive function in men: a randomized trial. Ann Intern Med. 2013;159(12):806–814.
35.
GuallarEStrangesSMulrowCAppelLJMillerERIII. Enough is enough: Stop wasting money on vitamin and mineral supplements. Ann Intern Med. 2013;159(12):850–851.
36.
KenslerTWWakabayashiNBiswalS. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol. 2007;47:89–116.
37.
WakabayashiNDinkova-KostovaATHoltzclawWD. Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers. Proc Natl Acad Sci U S A. 2004;101(7):2040–2045.
38.
de VriesHEWitteMHondiusD. Nrf2-induced antioxidant protection: a promising target to counteract ROS-mediated damage in neurodegenerative disease?Free Radic Biol Med. 2008;45(10):1375–1383.
39.
SpornMBLibyKT. NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer. 2012;12(8):564–571.
40.
LiJIchikawaTVillacortaL. Nrf2 protects against maladaptive cardiac responses to hemodynamic stress. Arterioscler Thromb Vasc Biol. 2009;29(11):1843–1850.
41.
TanYIchikawaTLiJ. Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo. Diabetes. 2011;60(2):625–633.
42.
LeeYShinDHKimJH. Caffeic acid phenethyl ester-mediated Nrf2 activation and IkappaB kinase inhibition are involved in NFkappaB inhibitory effect: structural analysis for NFkappaB inhibition. Eur J Pharmacol. 2010;643(1):21–28.
43.
Dinkova-KostovaATLibyKTStephensonKK. Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci U S A. 2005;102(12):4584–4589.
44.
YatesMSTauchiMKatsuokaF. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol Cancer Ther. 2007;6(1):154–162.
45.
ZhengHWhitmanSAWuW. Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes. 2011;60(11):3055–3066.
46.
WooSYKimJHMoonMK. Discovery of vinyl sulfones as a novel class of neuroprotective agents toward Parkinson’s disease therapy. J Med Chem. 2014;57(4):1473–1487.
47.
WengHLiXReeceEAYangP. SOD1 suppresses maternal hyperglycemia-increased iNOS expression and consequent nitrosative stress in diabetic embryopathy. Am J Obstet Gynecol. 2012;206(5):448. e1–e7.
48.
MaQ. Role of nrf2 in oxidative stress and toxicity. Ann Rev Pharmacol Toxicol. 2013;53:401–426.
CullinanSBGordanJDJinJHarperJWDiehlJA. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Mol Cell Biol. 2004;24(19):8477–8486.
51.
ZhangDDLoSCCrossJVTempletonDJHanninkM. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol. 2004;24(24):10941–10953.
52.
DhakshinamoorthySLongDJ2ndJaiswalAK. Antioxidant regulation of genes encoding enzymes that detoxify xenobiotics and carcinogens. Curr Top Cell Regul. 2000;36:201–216.
53.
ZhangDD. Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab Rev. 2006;38(4):769–789.
54.
KobayashiMYamamotoM. Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. Adv Enzyme Regul. 2006;46:113–140.
55.
CoppleIMGoldringCEKitteringhamNRParkBK. The Nrf2-Keap1 defence pathway: role in protection against drug-induced toxicity. Toxicology2008;246(1):24–33.
56.
HybertsonBMGaoB. Role of the Nrf2 signaling system in health and disease. Clin Genet. 2014;86(5):447–452.
57.
BhakkiyalakshmiESireeshDRajaguruPPaulmuruganRRamkumarKM. The emerging role of redox-sensitive Nrf2-Keap1 pathway in diabetes. Pharmacol Res. 2015;91:104–114.
58.
GarberK. Biochemistry: a radical treatment. Nature. 2012;489(7417):S4–S6.
59.
ChuengsamarnSRattanamongkolgulSLuechapudipornRPhisalaphongCJirawatnotaiS. Curcumin extract for prevention of type 2 diabetes. Diabetes Care. 2012;35(11):2121–2127.
60.
AnandPKunnumakkaraABNewmanRAAggarwalBB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807–818.
61.
LiHZhangLWangF. Attenuation of glomerular injury in diabetic mice with tert-butylhydroquinone through nuclear factor erythroid 2-related factor 2-dependent antioxidant gene activation. Am J Nephrol. 2011;33(4):289–297.
62.
HiroseMYadaHHakoiKTakahashiSItoN. Modification of carcinogenesis by alpha-tocopherol, t-butylhydroquinone, propyl gallate and butylated hydroxytoluene in a rat multi-organ carcinogenesis model. Carcinogenesis. 1993;14(4):2359–2364.
63.
PergolaPERaskinPTotoRD. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med. 2011;365(4):327–336.
64.
Di CarloGMascoloNIzzoAACapassoF. Flavonoids: old and new aspects of a class of natural therapeutic drugs. Life Sci. 1999;65(4):337–353.
65.
SinghPAnandAKumarV. Recent developments in biological activities of chalcones: a mini review. Eur J Med Chem. 2014;85:758–777.
66.
VahakangasKMyllynenP. Drug transporters in the human blood-placental barrier. Br J Pharmacol. 2009;158(3):665–678.
67.
RangelLPWinterEGauthierC. New structure-activity relationships of chalcone inhibitors of breast cancer resistance protein: polyspecificity toward inhibition and critical substitutions against cytotoxicity. Drug Des Devel Ther. 2013;7:1043–1052.
68.
ParveenZBrunhoferGJabeenIErkerTChibaPEckerGF. Synthesis, biological evaluation and 3D-QSAR studies of new chalcone derivatives as inhibitors of human P-glycoprotein. Bioorg Med Chem. 2014;22(7):2311–2319.
